Monitor future 8-K filings for initial grants under the 2026 Plan, which will reveal the actual dilution and compensation structure. The evergreen provision means share count will grow automatically each year unless the board opts out.
Price Chart
Executive Summary
Pelthos Therapeutics held its 2026 Annual Meeting on September 29, 2026, where stockholders approved the new 2026 Equity Incentive Plan, elected eight director nominees, and ratified Grant Thornton LLP as the independent auditor for FY2026. The 2026 Plan replaces the prior 2023 Plan and adds 500,000 new shares plus an evergreen provision. This is a routine governance filing with no material financial data or operational updates.
Key Facts
- Stockholders approved the 2026 Equity Incentive Plan with 2,698,543 votes for, 187,365 against, and 13 abstentions.
- The 2026 Plan adds 500,000 new shares of common stock to the equity reserve, plus any shares remaining or forfeited under the prior 2023 Plan.
- The 2026 Plan includes an evergreen provision that automatically increases the share reserve by 5% of outstanding common and Series A Convertible Preferred (as-converted) each fiscal year starting in 2027.
- All eight director nominees were elected with strong support (lowest 'for' votes: Matthew Pauls with 2,775,221).
- Grant Thornton LLP was ratified as independent auditor for FY2026 with 3,394,740 votes for, 1 against, and 1,353 abstentions.
- As of the August 4, 2026 record date, there were 3,828,469 shares of common stock and 52,128 shares of Series A Preferred Stock outstanding.
- 70.0% of voting power (3,396,094 votes) was present at the meeting, constituting a quorum.
Financial Impact
No financial data reported. The 2026 Equity Incentive Plan authorizes up to 500,000 new shares plus an evergreen provision, but no grants have been made under it yet.
Risk Factors
- Potential dilution from the 500,000 new shares plus annual evergreen increases starting in FY2027.
- No operational or financial performance data was disclosed in this filing.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001919246-26-000125 |
| Document: pths-20260929.htm | 0001919246-26-000125 |
| Document: 0001919246-26-000125-index-headers.html | 0001919246-26-000125 |
| Document: 0001919246-26-000125-index.html | 0001919246-26-000125 |
| Document: 0001919246-26-000125.txt | 0001919246-26-000125 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 24d ago | 8-K | $20.60 $20.50 | ▼ −0.49% | ▼ −1.65% | $17.01 (−17.43%) |
Aug 13, 2026 10w ago | 8-K | $28.95 $26.66 | ▲ +7.91% | ▲ +5.95% | $17.01 (+41.24%) |
Aug 3, 2026 12w ago | Press Release | $26.84 | awaiting T+5 | — | $17.01 (−36.62%) |
Jun 17, 2026 18w ago | Insider Cluster | $29.00 $29.21 | ▲ +0.72% | ▲ +2.39% | $17.01 (−41.34%) |
May 28, 2026 21w ago | 8-K | $26.47 $25.55 | ▼ −3.48% | ▼ −0.95% | $17.01 (−35.74%) |
May 22, 2026 22w ago | 144 | $26.66 $26.20 | ▼ −1.73% | ▼ −3.40% | $17.01 (−36.20%) |
May 21, 2026 22w ago | 8-K | $26.66 $26.20 | ▲ +1.73% | ▲ +3.38% | $17.01 (+36.20%) |
May 14, 2026 23w ago | 8-K | $27.69 $27.10 | ▼ −2.13% | ▼ −1.41% | $17.01 (−38.57%) |
May 14, 2026 23w ago | Press Release | $27.69 $27.10 | ▼ −2.13% | ▼ −1.41% | $17.01 (−38.57%) |
Apr 20, 2026 26w ago | 3 | $23.00 $24.97 | ▲ +8.57% | ▲ +7.48% | $17.01 (−26.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers